Assessing the Impact of Ultra-Low Cut Points in Immunogenicity Assays

Assessing the Impact of Ultra-Low Cut Points in Immunogenicity Assays
December 2, 2024 BioData Solutions

Ultra-low cut points for your Anti-Drug Antibody assays can sometimes be concerning. In partnership with ICON plc, we studied a few different datasets. Download the poster to learn about our observations.

Videos

Bioanalytical Components of INDs, NDAs, and BLAs | Mini-Learning

Bioanalytical Components of INDs, NDAs, and BLAs | Mini-Learning

Requirements for IND vs NDA/BLA | Micro-Learning

Requirements for IND vs NDA/BLA | Micro-Learning

Disease-Specific Matrix Specificity Testing for PK and ADA Methods for Large Molecules | Micro-Learning

Disease-Specific Matrix Specificity Testing for PK and ADA Methods for Large Molecules | Micro-Learning

Artificial Intelligence increases efficiencies and reduces bias for bioanalytical pharmacokinetic studies and anti-drug antibody statistical determinations

Artificial Intelligence increases efficiencies and reduces bias for bioanalytical pharmacokinetic studies and anti-drug antibody statistical determinations

App Notes

Cross-Validation of Statistical Workflow for Cut Point Calculation using Red Thread (Python) Vs R

Cross-Validation of Statistical Workflow for Cut Point Calculation using Red Thread (Python) Vs R

Comparing Cut Points Between Statistical Software Stata and R Using Random Effects Model

Comparing Cut Points Between Statistical Software Stata and R Using Random Effects Model

Videos

Turning a Potential BLA Crisis Into  Compliance Success: BioData’s Evidence Backed  ADA Strategy Wins Regulatory Approval

Turning a Potential BLA Crisis Into Compliance Success: BioData’s Evidence Backed ADA Strategy Wins Regulatory Approval

Simplifying Bioanalytical Review Using Advanced Computational Techniques

Simplifying Bioanalytical Review Using Advanced Computational Techniques

Posters

Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS)

Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS)

Assessing the Impact of Ultra-Low Cut Points in Immunogenicity Assays

Assessing the Impact of Ultra-Low Cut Points in Immunogenicity Assays

Singlet Analysis Yields Equivalent Results as Duplicate Analysis in Preclinical Immunogenicity Assessment

Singlet Analysis Yields Equivalent Results as Duplicate Analysis in Preclinical Immunogenicity Assessment

Can Automation Improve Compliance, Consistency, & Efficiency for CGTP Data Analysis

Can Automation Improve Compliance, Consistency, & Efficiency for CGTP Data Analysis

White Papers

Artificial Intelligence increases efficiencies and reduces bias for bioanalytical pharmacokinetic studies and anti-drug antibody statistical determinations

Artificial Intelligence increases efficiencies and reduces bias for bioanalytical pharmacokinetic studies and anti-drug antibody statistical determinations